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Abstract
Background: K2 products are synthetic cannabinoid-laced, marijuana-like drugs of abuse, use of which is often associated
with clinical symptoms atypical of marijuana use, including hypertension, agitation, hallucinations, psychosis, seizures and
panic attacks. JWH-018, a prevalent K2 synthetic cannabinoid, is structurally distinct from D
9-THC, the main psychoactive
ingredient in marijuana. Since even subtle structural differences can lead to differential metabolism, formation of novel,
biologically active metabolites may be responsible for the distinct effects associated with K2 use. The present study
proposes that K2’s high adverse effect occurrence is due, at least in part, to distinct JWH-018 metabolite activity at the
cannabinoid 1 receptor (CB1R).
Methods/Principal Findings: JWH-018, five potential monohydroxylated metabolites (M1–M5), and one carboxy metabolite
(M6) were examined in mouse brain homogenates containing CB1Rs, first for CB1R affinity using a competition binding
assay employing the cannabinoid receptor radioligand [
3H]CP-55,940, and then for CB1R intrinsic efficacy using an
[
35S]GTPcS binding assay. JWH-018 and M1–M5 bound CB1Rs with high affinity, exhibiting Ki values that were lower than or
equivalent to D
9-THC. These molecules also stimulated G-proteins with equal or greater efficacy relative to D
9-THC, a CB1R
partial agonist. Most importantly, JWH-018, M2, M3, and M5 produced full CB1R agonist levels of activation. CB1R-mediated
activation was demonstrated by blockade with O-2050, a CB1R-selective neutral antagonist. Similar to D
9-THC, JWH-018 and
M1 produced a marked depression of locomotor activity and core body temperature in mice that were both blocked by the
CB1R-preferring antagonist/inverse agonist AM251.
Conclusions/Significance: Unlike metabolites of most drugs, the studied JWH-018 monohydroxylated compounds, but not
the carboxy metabolite, retain in vitro and in vivo activity at CB1Rs. These observations, combined with higher CB1R affinity
and activity relative to D
9-THC, may contribute to the greater prevalence of adverse effects observed with JWH-018-
containing products relative to cannabis.
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Introduction
In recent years, several products sold as incense in headshops,
commonly referred to as ‘‘K2’’ and ‘‘Spice’’, have rapidly emerged
as legal substitutes for cannabis due to their cannabimimetic effects
when smoked or consumed [1]. Though marketed as ‘‘natural’’
herbal blends, K2 products are usually non-psychotropic plant
matter adulterated with various synthetic cannabinoids, most of
which are aminoalkylindoles (AAIs) of the JWH family, a series of
WIN-55,212-2 analogues created in 1994 by Dr. John W.
Huffman for structure-activity relationship studies of the canna-
binoid receptors [2,3]. They, along with other synthetic cannabi-
noids, such as CP-47,497 and HU-210, were first found in the
‘‘natural’’ herbal blends in 2008 [1,4,5,6]. One particular AAI,
JWH-018 [7] is quite prevalent across many different brands and
batches of K2 products [8,9]. JWH-018 and other cannabinoids,
such as D
9-tetrahydrocannabinol (D
9-THC), the major active
constituent in marijuana, produce their psychoactivity by binding
and activating, to varying degrees, cannabinoid 1 receptors
(CB1Rs) in the CNS, which are Gi/o-protein coupled receptors
(GPCRs) [10]. Although the desired effects of K2 products are
generally similar to those of marijuana, the adverse effect
frequency and severity of K2 is much greater than that of
marijuana, which has been used for millennia and is the most
commonly abused illegal drug in the U.S. [11]. While smoking or
oral consumption of marijuana acutely produces relatively mild
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21917and tolerable side effects in most users, such as appetite stimulation
and orthostatic hypotension, it very rarely causes the adverse
effects observed rather commonly with similar use of K2 products,
such as hypertension, agitation, hallucinations, psychoses, seizures
and panic attacks [1,4,12,13]. In extreme THC overdose cases,
similar symptoms can be observed but they are not typically
associated with THC use. In addition to acute adverse effects
produced by K2, a case report indicates that chronic abuse may
also result in a severe withdrawal and dependence syndrome [14].
The use of K2 has even been causally linked to at least one death
by overdose and has been implicated for likely involvement in
several other fatalities, resulting in over 2500 calls to poison
control centers in 2010 alone and numerous visits to emergency
departments across the United States [15,16,17] and Europe
[13,18].
These observations have garnered the attention of public health
and legislative officials in many municipalities, and have even
moved the US Drug Enforcement Administration (DEA) to use its
emergency powers to temporarily categorize JWH-018 and four
other synthetic cannabinoids as Schedule I substances for at least
one year because ‘‘…they impose imminent hazard to public
safety’’ [19]. Regardless of proactive legislative movements, these
products are still legal and available in most countries throughout
the world. Furthermore, the rapid increased use of K2 products
among youth, their current inability to be detected by standard
drug urine tests and the constant introduction of new structurally
similar products of unknown content pose a significant risk to
public health. Most importantly, the pharmacological and
toxicological profiles of these products are virtually unknown,
and the mechanisms underlying the discrepancies in the adverse
effect frequency and severity of K2 relative to the well-established
cannabis have yet to be elucidated.
JWH-018 activates CB1Rs with greater potency and efficacy
than D
9-THC [10,20]. While such pharmacodynamic differences
may explain some reports of toxicity, such as overdosing by users
expecting a cannabis-like potency, other mechanisms may also be
responsible for the distinct discrepancy in side effect severity often
observed for these two CB1R agonists. For instance, even very
high doses of marijuana are unlikely to acutely cause seizures or
permanent cardiac damage in otherwise healthy individuals as it
has been reported for K2 [21]. One likely mechanism underlying
these observations might result from unique pharmacokinetic
profiles for these two structurally distinct cannabinoids. For
example, although both compounds undergo Phase I metabolism
by cytochromes P450, JWH-018 has been shown to have at least
nine monohydroxylated metabolites whose biological activity is
currently undetermined [9], while D
9-THC has only one known
major psychoactive monohydroxylated metabolite, 11-OH-THC
[22]. Both D
9-THC and JWH-018 have been shown to be
metabolized to one primary carboxy metabolite [22,23]. Mass
spectral analysis of urine and serum samples collected from K2
users have also shown appreciable concentrations of several of the
hydroxylated JWH-018 metabolites [8,23] and our recent study
using authentic standards [24] confirmed that humans excrete four
of the metabolites examined in the current study (M2, M3, M5,
and M6) at levels ranging from 12 to 83 ng/mL. Although Phase I
hydroxylation is generally considered to result in an inactivation of
parent compounds, it is nevertheless possible that one or more
JWH-018 metabolites might instead display distinct pharmaco-
logical and/or toxicological properties. Therefore, we hypothe-
sized that the discrepancies in adverse effect frequency and
severity reported for D
9-THC relative to K2 might be due, in part,
to differences in the action of distinct monohydroxylated or
carboxy metabolites of JWH-018 relative to D
9-THC.
This hypothesis was tested in the present study by determining
the in vitro affinity for and intrinsic activity at CB1Rs of five
monohydroxylated (M1–M5, Fig. 1) and one carboxy derivative of
JWH-018 (M6, Fig. 1). Furthermore, to establish in vivo relevance,
the activity of JWH-018 and one of its metabolites exhibiting
similar in vitro potency and efficacy to D
9-THC were evaluated in
NIH Swiss mice by examining two endpoints from the standard
cannabinoid tetrad battery of tests. We report that several
hydroxylated derivatives of JWH-018 not only retain nanomolar
binding affinity for CB1Rs, but also exhibit a range of intrinsic
activities from partial to full agonism. This new information is
critical for understanding the pharmacological significance of
JWH-018 metabolites produced in humans.
Results
Five JWH-018 hydroxylated metabolites bind mouse
CB1R with affinities greater than or equal to that of D
9-
THC
The cannabis-like actions of JWH-018-containing products in
human users indicate a CB1R-dependent mechanism of action for
the parent compound and, potentially, its metabolites. Although
JWH-018 has been shown to bind to CB1Rs with high affinity
[10], to date, the action of its metabolites at this receptor is
unknown. Therefore, the present study employed a radiolabeled
competition binding assay to determine the affinity (Ki) of JWH-
018 and five monohydroxylated derivatives (M1–M5, Fig. 1) and
one carboxy metabolite (M6, Fig. 1) to CB1Rs in mouse whole
brain membrane homogenates. CB1Rs are endogenously ex-
pressed in abundant quantities in the CNS, while negligible levels
of CB2 receptors are present [25,26]. Therefore, brain tissue
provides a concentrated source of CB1Rs that is practically devoid
of CB2Rs and is therefore generally accepted for use in in vitro
CB1R studies [27,28]. Cannabinoids and all tested JWH-018
compounds (M1–M6) were evaluated for the ability of increasing
concentrations to compete against the radiolabeled cannabinoid
[
3H]CP-55,940 for binding to CB1Rs. Data are expressed as the
percent specific binding occurring at each drug concentration
relative to the level of binding present in the presence of vehicle
only. Saturation binding with [
3H]CP-55,940 showed that mouse
brain homogenates contain a CB1R density of 2.4460.15 pmole/
mg protein, to which [
3H]CP-55,940 binds with an affinity (Kd)o f
0.3760.07 nM (n=3, data not shown). D
9-THC, JWH-018 and
M1–M5 produce 100% displacement of [
3H]CP-55,940 from
CB1Rs (data not shown) and bind with affinities (Ki) in the low 2–
30 nM range with a rank order of JWH-018=M1.M2.D
9-
THC=M3=M4=M5&M6 (Fig. 2). Importantly, M1 retains
CB1R affinity (2.660.3 nM) similar to that of the parent
compound (1.260.3 nM), while the carboxy derivative M6 fails
to bind to CB1Rs. It is also significant to note that JWH-018 and
M1 bind to CB1Rs with almost 10-fold higher affinity than D
9-
THC (15.2964.5 nM) and all other tested compounds (except
M6) also bind to mCB1Rs with equivalent affinity relative to D
9-
THC. The Ki values determined here for CP-55,940, D
9- THC,
and JWH-018 agree well with those previously reported for these
cannabinoids of 0.5–5 nM, 5.05–80.3 nM, and 9.0 nM, respec-
tively [29,30].
JWH-018 and M1–M5 activate mouse CB1Rs with a range
of low partial to full agonism
Subsequent studies employing the [
35S]GTPcS binding assay
characterized the intrinsic efficacy of these compounds at CB1Rs
by examining their ability to activate G-proteins (Fig. 3). Similar to
previous reports [31], a receptor saturating concentration (10 mM)
CB1R-Active JWH-018 Hydroxylated Metabolites
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G-protein stimulation than a similar maximal concentration of the
partial CB1R agonist D
9-THC (0.3960.02 vs. 0.0760.01 pmole/
mg, Fig. 3A). JWH-018 and M1–M5 act as partial (D
9-THC, M1,
M4) or full (CP-55,940, JWH-018, M2, M3, M5) agonists at
mCB1Rs. For example, a receptor saturating concentration of
JWH-018 and M2 produces 0.2960.02 and 0.3260.03 pmole/
mg stimulation of G-proteins, respectively. Although this level of
activation is slightly less, it is not significantly different than the
amount of activation produced by the full agonist CP-55,940.
Importantly, JWH-018 and 5 of the 6 oxidized products of JWH-
018 tested produce equivalent (M4) or greater (JWH-018, M1,
M2, M3, M5) levels of G-protein stimulation than D
9-THC. The
activation of G-proteins produced by CP-55,940, JWH-018, M1
and D
9-THC is also concentration-dependent (Fig. 3B) and occurs
with an identical rank order of potency as predicted by the affinity
of these compounds for CB1Rs, with EC50 values of 3.366
2.35 nM, 6.8262.48, 17.0169.59 and 167.4684.7 nM, respec-
tively (Fig. 2). In agreement to data presented in Fig. 3A, the
maximal efficacy (Emax) of G-protein activation in this assay for
CP-55,940, JWH-018, M1 and D
9-THC were 0.2860.02 pmole/
mg, 0.2960.02 pmole/mg, 0.1960.02, and 0.0660.01. Concen-
tration-dependence and agreement between the rank order of
receptor affinity and the potency for G-protein activation provide
strong evidence for a receptor-mediated mechanism, most likely
via CB1Rs. Lastly, G-protein activation produced by an ED90
concentration of all cannabinoids and metabolites examined (e.g.,
100 nM, estimated from Fig. 3B) was significantly attenuated by
co-incubation with a receptor saturating concentration (1 mM) of
the selective CB1R neutral antagonist O-2050 (Fig. 3C).
D
9-THC, JWH-018 and M1 reduce locomotor activity and
core body temperature by a CB1R-dependent
mechanism
The specific mechanism underlying whole-animal effects
produced by suspected cannabinoids can be validated in vivo by
measuring standard, well-documented physiological parameters
that are consistently altered by CB1R activation in rodents (e.g.,
the cannabinoid ‘‘tetrad’’ [32]). In the present study, two of the
four parameters associated with the cannabinoid tetrad, locomotor
activity and core body temperature, were measured in mice. As
Figure 1. Structures of JWH-018 and six JWH-018 hydroxylated products. A. JWH-018 [(1-pentyl-1H-indol-3-yl)-1-naphthalenyl-
methanone] B. M1 [(4-hydroxy-1-pentyl-1H-indol-3-yl)(naphthalen-1-yl)methanone] C. M2 [(5-hydroxy-1-pentyl-1H-indol-3-yl)(naphthalen-1-
yl)methanone] D. M3 [(6-hydroxy-1-pentyl-1H-indol-3-yl)(naphthalen-1-yl)methanone] E. M4 [(7-hydroxy-1-pentyl-1H-indol-3-yl)naphthalen-1-
yl)methanone] F. M5 [(1-(5-hydroxypentyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone] G. M6 [5-(3-(1-naphthoyl)-1H-indol-1-yl)pentanoic acid].
doi:10.1371/journal.pone.0021917.g001
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by intraperitoneal (i.p.) administration of 30 mg/kg D
9-THC
(Figs. 4 and 5). Furthermore, i.p. administration of 3 mg/kg of
JWH-018 and 10 mg/kg M1 also reduces natural exploratory
behavior in a novel environment to levels equivalent to that
produced by 30 mg/kg of D
9-THC over a 10 hr observation
period (Fig. 4A). The effect of D
9-THC, JWH-018 and M1 on
locomotor activity is significantly attenuated by pretreatment of
mice with a 10 mg/kg dose of the CB1-preferring antagonist/
inverse agonist AM-251 (Fig. 4B) (P#0.001 across all groups,
H=30.000 with 7 DF). The same doses of all three compounds
also produce a significant decrease in core body temperature
relative to vehicle-treated controls, beginning between 30 and
60 min after injection (P,0.001 across all groups, F=15.704 with
7 DF). Peak temperature depression, as well as the rate of
temperature recovery is much greater for JWH-018 and M1 than
for D
9-THC (Fig. 5A) and is ultimately reflected by similar area
under the curve values when averaged across the entire 10 hr
observation period (Fig. 5B). Similar to effects on locomotor
activity, pretreatment with AM-251 (10 mg/kg) restored core
body temperature to control levels, signifying a CB1R-dependent
mechanism.
Discussion
This study importantly demonstrates for the first time that five
potential Phase I hydroxylated metabolites of the synthetic
cannabinoid JWH-018 bind with high nanomolar affinity to,
and very efficaciously activate, CB1Rs in vitro. Furthermore, the
sharp decrease in locomotor activity and core body temperature in
mice produced by the M1 derivative of JWH-018 and the reversal
of these effects by a CB1R-preferring antagonist indicate that
potential metabolites of this emerging drug of abuse are active in
vivo as well. Importantly, JWH-018 and most of the tested
derivatives apparently elicit greater in vitro and in vivo responses
relative to D
9-THC, the well-known classical cannabinoid present
in marijuana. By comparison, all D
9-THC metabolites, except
one, are inactivated by oxidative metabolism, which prevents
further CB1R activation. The higher affinity, potency and efficacy
of JWH-018, coupled with its potential metabolism to a number of
equally active metabolites, suggests that both acute and chronic
effects of JWH-018 might be intensified when compared to a
similar level of exposure to D
9-THC. Taken collectively, the results
presented here suggest that differences in both the pharmacody-
namic and pharmacokinetic properties of JWH-018 relative to D
9-
THC might help to explain the distinct adverse clinical
manifestations often observed with K2 use. While the present
study reveals the ability of these JWH-018 derivatives to act at
CB1Rs, pharmacokinetic analysis will be required to definitively
determine the presence of these metabolites in target tissues in
collective concentrations high enough to elicit adverse effects in
vivo. The recent discovery of detectable nanomolar concentrations
of M2, M3, and M5, the most efficacious of the JWH-018
derivatives examined in this study, in human urine [24], supports
the current proposal that metabolites contribute to the effects of
K2 and should thus be pursued further.
The emergence of ‘‘legal highs’’ in response to synthetic
cannabinoid use is relatively new [5] and the field is still in its
infancy; hence, limited studies have examined the pharmacolog-
ical or toxicological properties of K2 products and their active
components. Moreover, the main foci of the current K2 literature
are only clinical case studies reported from emergency depart-
ments [12,13,14,15,16,18] and methods detailing the analytical
detection of synthetic K2 cannabinoids in body fluids
Figure 2. JWH-018 and M1–M5 bind CB1R with equal or greater affinity than D
9-THC. JWH-018 and M1, M2, M3, M4, M5, but not M6,
completely displaced the radiolabeled cannabinoid [
3H]CP-55,940 from CB1Rs (data not shown). Affinities for CB1Rs of JWH-018 and M1–M5 were
equivalent to or up to 10-fold greater than that of D
9-THC (*P,0.05, **P,0.01, ***P,0.001 relative to D
9-THC, one way ANOVA with Dunnett’s
Multiple Comparison Test, n=3–4).
doi:10.1371/journal.pone.0021917.g002
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growing use and dangerous adverse effect profile of K2 products, it
is critical that clinicians and basic scientists obtain a strong
mechanistic understanding of the cannabinoid constituents in K2,
so these drugs can be identified, regulated and therapies designed
to address the adverse effects.
Currently, little is known regarding the structure-activity
relationships (SARs) at CB1R of aminoalkyindole cannabimi-
metics that are substituted around the indole nucleus, especially at
positions 4–7. Although Eissenstat et al. [34] examined a number
of substitutions, their significant findings focused on the impor-
tance of substitutions at positions 1–3. To our knowledge, the
present work is the first to show that hydroxylation at positions 5
and 6 (metabolites M2 and M3) retain significantly higher activity,
with little difference in affinity, compared to hydroxylation at
positions 4 and 7 (M1 and M4). The importance of the substituent
at the end of the pentyl chain is also underscored in the present
work by the observation that addition of a carboxylic acid (M6),
but not a hydroxyl group (M5) totally eliminates affinity for CB1R.
Detailed characterization of the specific enzymes responsible for
biotransformation of JWH-018 and structurally similar synthetic
cannabinoids would be an important step to fully understand the
consequences of JWH-018 use in humans. A recent report,
employing crude human liver microsomes, suggests that specific
isoforms of the cytochromes P450 system are essential for
metabolism of JWH-018 to various mono- and dihydroxylated
metabolites [9], including the metabolites examined in the present
study. Likewise, a second in vitro study, using rat liver microsomes
[35], has identified the cytochrome P450 system responsible for
metabolism of the structurally similar CB2 selective agonist JWH-
015. However, to our knowledge, no study has reported the specific
enzymes responsible for production of the primary and secondary
metabolites of JWH-018. When delineated, SARs, mutagenesis
and polymorphism studies of these specific enzymes might reveal
inter-individual differences for production of active metabolites
and thus provide support for why some individuals exhibit greater
degrees of severe adverse reactions to K2 exposure. If correlated to
clinical observations, this information could provide a model to
predict severe adverse effects in susceptible individuals. For
example, different enzymatic polymorphisms may yield distinct
metabolic rates that vary from person to person and produce a
preference for formation of certain metabolites relative to others.
As predicted by the present study, because different metabolites
exhibit various degrees of activity, a bias towards production of
more active metabolites that could increase the net activation of
CB1R is possible. Alternatively, it might be predicted that
production of less active metabolites by certain individuals would
result in antagonistic effects with concurrently administered
cannabinoids, potentially leading to greater use of synthetic
cannabinoids in an attempt to overcome the reduction in effects.
Although speculative, it is possible that biased metabolic profiles
could produce a mix of active metabolites, producing a multitude
of ‘‘entourage effects’’ associated with use of JWH-018. Such
complex effects could have unique and potentially harmful
consequences on the delicate balance of the endocannabinoid
system, which plays important roles in modulating mood [36],
appetite and energy homeostasis [37,38], pain sensation [39],
immune function [40], fertility [41] and possibly bone homeostasis
[42].
The [
35S]GTPcS binding experiments presented in the current
study indicate that several potential JWH-018 hydroxylated
metabolites activate G-proteins in mouse brain that cannot be
completely antagonized by the CB1R neutral antagonist O-2050.
Although several explanations are possible, cannabinoid receptor-
independent GPCR activation in response to K2 use is probable.
The possibility of CB1R-independence, both GPCR and non-
GPCR mediated, is supported by the clinical observations of
seizures, hallucinations, anxiety, agitation, panic attacks, and
hypertension, which are not typically observed following CB1R
activation. The mechanisms behind these atypical adverse effects,
although not completely understood themselves, nevertheless give
additional information as to how K2 is acting in vivo. For example,
Figure 3. JWH-018 and M1–M5 activate CB1R. A. Ten mM
concentrations of JWH-018, M1, M2, M3, and M5 activated brain GPCRs
greater than 10 mM D
9-THC. Activation by JWH-018, M2, M3 and M5 did
not differ from the full CB1R agonist CP-55,940. Values designated with
different letters above the error bars are significantly different (P,0.05,
one way ANOVA with Tukey’s Multiple Comparison post-hoc Test, n=3–
10). B. JWH-018 and M1 stimulated G-proteins more potently and
efficaciously than D
9-THC, n=3–4. C. GPCR activation by an estimated
ED90 concentration (100 nM) of metabolites was blocked by co-
incubation with 1 mM of the selective neutral CB1R antagonist O-2050
(**P,0.01, ***P,0.001 vs drug alone, Student’s t-test, n=3–7).
doi:10.1371/journal.pone.0021917.g003
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excessive, aberrant neural synaptic firing that leads to involuntary
tonic-clonic spasms. The mechanisms behind grand mal seizures
are complex and diverse, but ultimately involve disinhibition of
excitatory neurons [43]. Retrograde activation of CB1Rs by
cannabinoids and endocannabinoids hyperpolarizes presynaptic
neurons and thus inhibits synaptic transmission [44], and several
cannabinoids have even been shown to exhibit anticonvulsive
activity [45,46,47,48]. Therefore, seizures caused by K2 are
possibly due to the antagonism of other inhibitory networks, such
as GABA channels [49], and/or the activation of excitatory
networks, such as metabotropic glutamate receptors (mGluRs)
[50], Na
+ channels [51], and Ca
2+ channels [43]. Hallucinations,
as well as psychosis in susceptible individuals with a previous
personal and/or family psychiatric history [12,13], have also been
associated with K2 use. Theories underlying the neurobiological
mechanisms of hallucinations and psychosis include abnormal
dopaminergeric neurotransmission, as described in the dopamine
hypothesis of schizophrenia [52], serotonergic transmission, as
seen with the serotonergic classical hallucinogens [53], and
NMDA glutamate receptor blockade [54]. The cardiovascular
symptoms, as well as drug-induced anxiety, agitation and panic
attacks, associated with K2 use could be caused by activation of a1,
b1 and b2 adrenoceptors [55,56]. Activation of mGluRs [50], as
well as GABA channel blockade [57], may also be responsible for
anxiety due to K2. Alteration of the receptor networks mentioned
Figure 4. JWH-018 and M1 decreased mouse locomotor activity in a CB1R-dependent manner, similar to D
9-THC. A. Intraperitoneal
(i.p.) administration of 3 mg/kg JWH-018, 10 mg/kg JWH-018 M1, and 30 mg/kg D
9-THC decreased locomotor activity relative to vehicle controls over
a 10 h time course, beginning 60 min after injection. B. Area under the curve data generated from the 10 h time-course shows 3 mg/kg JWH-018,
10 mg/kg JWH-018 M1, and 30 mg/kg D
9-THC significantly decrease locomotor activity relative to vehicle controls (*P,0.05 vs. vehicle controls,
Kruskal-Wallis one-way ANOVA with Tukey HSD test, n=5). Co-administration of each cannabinoid with the CB1R-preferring antagonist/inverse
agonist AM251 (10 mg/kg) restored locomotor activity to vehicle control levels.
doi:10.1371/journal.pone.0021917.g004
Figure 5. JWH-018 and M1 decreased mouse core body temperature in a CB1R-dependent manner similar to D
9-THC. A. Mice
administered 3 mg/kg JWH-018 and 10 mg/kg M1 (i.p.) exhibited greater depressions in core body temperature than 30 mg/kg D
9-THC, but also
recovered more quickly over a 10 h time course, resulting in B. equivalent area under the curve values, which were significantly lower than vehicle
controls (*P,0.005 vs. vehicle controls, one-way ANOVA with Tukey HSD test, n=5). Core body temperature was restored to vehicle control levels by
coadministration of cannabinoids with the CB1R-preferring antagonist/inverse agonist AM251 (10 mg/kg).
doi:10.1371/journal.pone.0021917.g005
CB1R-Active JWH-018 Hydroxylated Metabolites
PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e21917here are just a few examples of many possible that may result in
severe adverse effects seen in an alarmingly large proportion of K2
users.
The present study investigates some previously unknown actions
of oxidized products of JWH-018 produced by using the relatively
new and increasingly common drug of abuse, K2. Although JWH-
018 is a predominant component of K2, it is unfortunately only
one of a whole host of cannabimimetic compounds found in
varying, unregulated concentrations from brand-to-brand and,
even within brands, batch-to-batch of K2. This reality presents a
challenge to researchers and clinicians in their attempts to better
understand and predict the biological consequences of K2 use and
thus accurately warn the general public about its risks, as well as
advise legislators, who are currently working to determine the
appropriate legal status of K2. The uncontrolled and heteroge-
neous nature of K2 also presents a danger to even its more
experienced users who may unknowingly use K2 containing
particular synthetic cannabinoid blends to which they may have
an adverse reaction. Nonetheless, this work represents an
important initial step toward understanding K2 by uncovering
significant CB1R affinities and intrinsic activities of five potential
metabolites of JWH-018. Many of the synthetic cannabinoids
found in K2 are aminoalkylindoles of the JWH family and are
quite structurally similar to JWH-018. Since JWH-018 produces
metabolites with partial to full agonist activity at CB1Rs, it is
justified to posit that similar K2 synthetic cannabinoids can also be
biotransformed into molecules with various levels of affinity and
activity at CB1Rs, as well as at other receptor systems as discussed
above. Altogether, the presence of parent synthetic cannabinoid
molecules within a single dose of K2, combined with the respective
active metabolites produced, could conceivably act in concert to
produce the dynamic range of effects observed following use of
various K2 preparations. The idea that active metabolites are
generated from not just one, but several parent molecules found
within a single drug of abuse, is novel and exciting, but
complicates matters by introducing an intrinsic polypharmacy
effect. Therefore, much future investigation is required to fully
elucidate human metabolic products to better assess which
oxidized products of JWH-018 retain pharmacological activity,
the relative contributions of each product and any synergistic/
antagonistic interactions between molecules. In conclusion, the
discovery that JWH-018 metabolites, and other oxidized products
of JWH-018, partake actively and diversely in the activity of K2
provides a substantial avenue of exploration and thus serves as an
essential building block in combating problems associated with an
increasingly common drug of abuse.
Materials and Methods
Materials
All drugs used for in vitro assays were diluted to a stock
concentration of 10
23 M with 100% ethanol and stored at
220uC. JWH-018 and its potential metabolites (M1–M6) were
purchased from Cayman Chemical (Ann Arbor, MI), who
chemically synthesized the metabolites and determined structures
through mass spectrometry and NMR. D
9-THC was supplied by
the National Institute on Drug Abuse (NIDA, Bethesda, MD).
WIN-55, 212-2, CP-55,940, AM-251, and O-2050 were pur-
chased from Tocris Bioscience (Ellisville, MO). GTPcS and GDP
used in the [
35S]GTPcS assay were purchased from EMD
Chemical (Gibbstown, NJ), and Sigma Aldrich (St. Louis, MO),
respectively. Both chemicals were diluted to a stock concentration
of 10
22 M with water and stored at 220uC. [
3H]CP-55,940
(174.6 Ci/mmol) used for competition receptor binding was
purchased from PerkinElmer (Waltham, MA) and [
35S]GTPcS
(1250 Ci/mmol) was purchased from American Radiolabeled
Chemicals (St. Louis, MO). For in vivo studies, all drugs were
dissolved to the appropriate concentrations in a ratio of 1:1:18 of
absolute ethanol: emulphor: physiological saline vehicle and stored
at 4uC until used.
Membrane Preparation
Whole brains were harvested from decapitated B6SJL mice,
snap-frozen in liquid nitrogen, and stored at 280uC. To prepare
crude membrane homogenates, brains were thawed on ice, pooled
and suspended in ice-cold homogenization buffer (50 mM HEPES
pH 7.4, 3 mM MgCl2, and 1 mM EGTA) [58]. Suspended brains
were then subjected to 10 complete strokes employing a 40 mL
Dounce glass homogenizer, and centrifuged at 40,0006 g for
10 min at 4uC. Supernatants were discarded and pellets were
resuspended in ice cold homogenization buffer, homogenized and
centrifuged similarly twice more. Following the final centrifugation
step, pellets were resuspended in ice-cold 50 mM HEPES, pH 7.4,
to a concentration of approximately 2 mg/mL and aliquoted for
storage at 280uC. Protein concentration was determined using
BCA
TM Protein Assay (Thermo Scientific, Rockford, IL).
Competition Receptor Binding Assay
Fifty mg of mouse brain membrane homogenates (containing a
relatively pure source of CB1Rs) were incubated with 0.2 nM of
the radiolabeled cannabinoid agonist [
3H]CP-55,940 for 90 min
at room temperature in an assay buffer containing 5 mM MgCl2,
50 mM Tris, 0.05% bovine serum albumin (BSA) and increasing
concentrations (0.1 nM–10 mM) of JWH-018 M1–M6, or non-
radioactive CP-55,940. Assays were performed in triplicate, in a
final volume of 1 mL, as previously described [59]. Total binding
was defined as the amount of radioactivity observed when 0.2 nM
[
3H]CP-55,940 was incubated in the absence of any competitor.
Nonspecific binding was defined as the amount of [
3H]CP-55,940
binding remaining in the presence of 10 mM of the non-radio-
active CB1/CB2 cannabinoid agonist WIN-55,212-2. Specific
binding was calculated by subtracting non-specific from total
binding. Reactions were terminated by quick filtration through
Whatman GF/B glass fiber filters, followed by five washes with an
ice-cold buffer containing 50 mM Tris and 0.05% bovine serum
albumin (BSA). Filters were punched out into 7 mL scintillation
vials and immersed in 4 mL of ScintiVerse
TM BD Cocktail scinti-
llation fluid. After overnight extraction, bound radioactivity was
determined by liquid scintillation spectrophotometry. Specific
binding is expressed as a percentage of binding occurring in
vehicle samples (e.g., binding in the absence of any competitor).
[
35S]GTPcS Binding Assay
[
35S]GTPcS binding was performed as previously described
[60], with minor modifications. Each drug to be tested was
incubated with 25 mg of mouse brain membrane homogenates,
10 mM GDP, 0.1 nM [
35S]GTPcS and assay buffer (20 mM
HEPES, 10 mM MgCl2, 100 mM NaCl, 20 units/L adenosine
deaminase, 0.05% BSA). Assays were performed in triplicate in a
final volume of 1 mL for 30 min at 30uC. Total binding was
defined as the amount of radioactivity observed when 0.1 nM
[
35S]GTPcS was incubated in the absence of any cannabinoid.
Nonspecific binding was defined as the amount of [
35S]GTPcS
binding remaining in the presence of 10 mM of non-radioactive
GTPcS. Specific binding was calculated by subtracting non-
specific from total binding. Reactions were terminated by quick
filtration through Whatman GF/B glass fiber filters, followed by
five washes with an ice-cold buffer containing 20 mM HEPES and
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and immersed in 4 mL of ScintiVerse
TM BD Cocktail scintillation
fluid. After overnight extraction, bound radioactivity was deter-
mined by liquid scintillation spectrophotometry. Specific binding is
expressed as picomoles of [
35S]GTPcS bound per mg of protein.
Animal Care and Use
Prior to surgery (see below), male NIH Swiss mice (Harlan
Sprague Dawley Inc., Indianapolis, IN), weighing approximately
25–30 g, were housed 3 animals per Plexiglas cage (15.24625.40
612.70 cm) in a temperature-controlled room at the University of
Arkansas for Medical Sciences. Room conditions were maintained
at an ambient temperature of 2262uC at 45–50% humidity.
Lights were set to a 12-h light/dark cycle. Animals were fed Lab
Diet rodent chow (Laboratory Rodent Diet #5001, PMI Feeds,
Inc., St. Louis, MO) and water ad libitum until immediately before
testing. Animals were acclimated to the laboratory environment 2
days prior to experiments and were tested in groups of 6 mice per
condition. All studies were carried out in accordance with the
Declaration of Helsinki and with the Guide for Care and Use of
Laboratory animals as adopted and promulgated by the National
Institutes of Health. Experimental protocols were approved by the
Animal Care and Use Committee at the University of Arkansas for
Medical Sciences (Animal Use Protocol #3155).
Core Temperature and Locomotor Activity
Measurements
Following appropriate anesthetization with ketamine (100 mg/
kg, intraperitoneal [i.p.]) and xylazine (10 mg/kg, i.p.), the
abdominal area of each mouse was shaved and sanitized with
iodine swabs. A rostral-caudal cut approximately 1.5 cm in length
was made with skin scissors, providing access to the intraperitoneal
cavity. A cylindrical glass -encapsulated radiotelemetry probe
(model ER-4000 E-Mitter, Mini Mitter, Bend, OR, USA) was
then inserted, and the incision was closed using absorbable 5-0
chromic gut suture material. At least 7 days were imposed between
surgery and experimental observation of drug effects to allow
incisions to heal and mice to recover normal body weights.
Following surgery, implanted mice were individually housed in
Plexiglas mouse cages (15.24625.40612.70 cm) for the duration
of all temperature and locomotor activity experiments. Implanted
transmitters produced activity- and temperature-modulated signals
that were transmitted to a receiver (model ER-4000 Receiver,
Mini Mitter Co., Inc.) underneath each mouse cage. Receivers
were housed in light- and sound-attenuating cubicles (Med
Associates model ENV-022MD, St. Albans, VT) equipped with
exhaust fans, which further masked ambient laboratory noise. On
experimental days, mice were weighed, marked, and returned to
their individual cages during which at least 1 hr of baseline data
were collected. Cannabinoid doses were then calculated and drugs
prepared for injection. Animals were subsequently removed from
their cage and injected with various doses of D
9-THC, JWH-018,
M1 or an equivolume of vehicle. Mice were then placed into a new
cage with fresh bedding to stimulate exploratory behavior.
Temperature and locomotor activity data were collected at regular
5-min intervals and processed simultaneously by the Vital View
data acquisition system (Mini Mitter Co., Inc.) for at least 8 hrs.
Statistical Analysis
Curve fitting and statistical analyses for in vitro experiments were
performed using GraphPad Prism version 4.0b (GraphPad
Software Inc., San Diego, CA). The Cheng-Prusoff equation
[61] was used to convert the experimental IC50 values obtained
from competition receptor binding experiments to Ki values, a
quantitative measure of receptor affinity. Non-linear regression for
one-site competition was used to determine the IC50 for compe-
tition receptor binding. Curve fitting of concentration-effect curves
via non-linear regression was also employed to determine the EC50
(a measure of potency) and Emax (a measure of efficacy) for
[
35S]GTPcS experiments. Data are expressed as mean 6 SEM. A
one-way ANOVA, followed by Tukey’s Multiple Comparison post-
hoc Test, was used to determine statistical significance (P,0.05)
between three or more groups.
For core body temperature experiments, the area under the
curve (AUC) was calculated using a trapezoidal rule from 0–10 hr.
For locomotor activity, total locomotor counts were summed from
0–10 hr. For temperature data, statistical significance (P,0.05)
was determined using a one-way ANOVA, followed by Tukey’s
HSD post-hoc test. Locomotor data were not normally distributed;
therefore, a Kruskal-Wallis one-way ANOVA on ranks was
performed, and all pairwise comparisons were then made using
the Tukey’s HSD test. All in vivo statistical calculations were
performed using SigmaStat 3 (Systat Software, Inc., San Jose, CA).
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